Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation.
Doshi SK, Kar S, Nair DG, Waggoner T, Agarwal H, Moussavian M, Kashani A, Oza S, Feldman L, Sadhu A, DeLurgio D, Alli O, Nielsen-Kudsk JE, Yamamoto M, Alkhouli M, Camm AJ, Coylewright M, Gibson CM, Granger CB, Gurol ME, Huber KC, Mansour M, Natale A, Pocock SJ, Reddy VY, Saliba WI, Asch FM, Wehrenberg S, Frost K, Christen T, Sutton BS, Stein KM, Leon MB, Ellenbogen KA; CHAMPION-AF Investigators.
Doshi SK, et al. Among authors: sutton bs.
N Engl J Med. 2026 Jun 4;394(21):2083-2094. doi: 10.1056/NEJMoa2517213. Epub 2026 Mar 28.
N Engl J Med. 2026.
PMID: 41910347
Clinical Trial.
The primary efficacy end point - a composite of death from cardiovascular causes, stroke, or systemic embolism - was tested for noninferiority (noninferiority margin, 4.8 percentage points) after 3 years of follow-up. ...CONCLUSIONS: Among patients with atrial fibrillation …
The primary efficacy end point - a composite of death from cardiovascular causes, stroke, or systemic embolism - was tested for nonin …